Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thomas Kalmus Eliasz
Observed names:
T Kalmus Eliasz,
T. Kalmus Eliasz
OpenAlex ID:
A5086155172
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
324
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
129
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023
·
O Abani
, A Abbas
, et al.
·
The Lancet Diabetes & Endocrinology
·
41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024
·
Saul N Faust
, Richard Haynes
, et al.
·
The Lancet Child & Adolescent Health
·
39
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O Abani
, A Abbas
, et al.
·
The Lancet Infectious Diseases
·
12
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O. Abani
, A. Abbas
, et al.
·
EClinicalMedicine
·
5
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O Abani
, A Abbas
, et al.
·
The Lancet Infectious Diseases
PDF
Show more works
View as search
Works count:
7
Citation count:
550
H-index:
5
I10-index:
5
Year
Topic
Type
